Clinical Trials Logo

Clinical Trial Summary

This study is designed to determine if magnetic resonance imaging (MRI) measures can be used to diagnose and monitor the progression of Parkinson's disease (PD) while distinguishing between PD and parkinsonisms [conditions that are PD look-a-like diseases such as progressive supranuclear palsy (PSP) or multiple system atrophy (MSA)] when combined with changes in certain proteins in body fluids that are related to iron (Fe).


Clinical Trial Description

The lack of in vivo biomarker(s) reflecting Parkinson's disease (PD)-related cell loss and associated pathoetiological/physiological processes in nigrostriatal structures has hindered discovery research and limited the ability to evaluate disease-modifying therapies. Recent research has generated excitement for using DTI and R2* MRI measures as biomarker(s) for PD-related pathology in nigrostriatal pathways, but they fall short by the lack of understanding of their clinical implications and biological/pathological underpinnings. Working closely with the National Institute of Neurological Disorders and Stroke (NINDS) Parkinson's Disease Biomarkers Program (PDBP), the proposed work will investigate multimodal MRI techniques in combination with fluid-based iron (Fe) protein profiles to serve as in vivo markers for PD-related nigrostriatal pathology that can be used as biomarkers for diagnosing PD, following its progression, and gaining mechanistic understanding of PD pathoetiology and pathophysiology. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT01888185
Study type Observational
Source Milton S. Hershey Medical Center
Contact
Status Completed
Phase
Start date December 2012
Completion date December 31, 2019

See also
  Status Clinical Trial Phase
Recruiting NCT02194816 - Modifiable Variables in Parkinsonism (MVP)
Recruiting NCT04876326 - Potential Use of Autologous and Allogeneic Mesenchymal Stem Cells in Patients With Multiple System Atrophy N/A
Active, not recruiting NCT05127057 - Proactive and Integrated Management and Empowerment in Parkinson's Disease (PRIME-UK): A New Model of Care (PRIME-RCT) N/A
Enrolling by invitation NCT01453127 - DaTSCAN Imaging in Aging and Neurodegenerative Disease Phase 4
Completed NCT01174771 - Repetitive Transcranial Magnetic Stimulation (TMS) for Progressive Supranuclear Palsy and Corticobasal Degeneration N/A
Completed NCT03314610 - Effect of Need to Void on Parkinsonian Gait
Recruiting NCT05506891 - Efficacy and Safety of Astragalus for Non-motor Symptoms of α-Synucleinopathy Phase 2
Completed NCT00950196 - Amantadine for Improving Neurologic Symptoms in Ataxia-Telangiectasia Phase 4
Recruiting NCT03924414 - Trial of Parkinson's And Zoledronic Acid Phase 4
Enrolling by invitation NCT05514106 - MIBG in Aging and Neurologic Disorders Phase 4
Completed NCT01581645 - Mobilaser Study to Help With People Who Are Having Problems With Their Gait Phase 0
Not yet recruiting NCT00767546 - Botulinum Toxin for Treatment of Seborrhic Dermatitis in Parkinsonian Patients Phase 1
Completed NCT02214862 - 2-(1-{6-[(2-[F-18]Fluoroethyl) (Methyl)Amino]-2-naphthyl} Ethylidene) Malononitrile-PET for in Vivo Diagnose of Tauopathy in Unclassified Parkinsonism Phase 0
Recruiting NCT04518059 - Misfolded Proteins in the Skin of People With Parkinson's Disease and Other Parkinsonism
Completed NCT03076671 - More Than a Movement Disorder: Applying Palliative Care to Parkinson's Disease N/A
Withdrawn NCT01329926 - Molecular Analysis of Human Neural Stem Cells
Terminated NCT00745030 - Efficacy and Tolerability of Ramelteon in Patients With Rapid Eye Movement (REM) Behavior Disorder and Parkinsonism N/A
Completed NCT04222218 - Cerebellar rTMS Theta Burst for Postural Instability in Progressive Supranuclear Palsy N/A
Completed NCT03386669 - Novel Neuroimage Study in Tauopathies With Parkinsonism Phase 2
Completed NCT02064543 - Measurement of Gait Using Opal APDM and Gait Mat in Parkinsonism